By reducing caloric intake through appetite suppression, improving insulin sensitivity, and directly stimulating hepatic lipid clearance, retatrutide may address multiple drivers of metabolic dysfunction-associated steatotic liver disease (MASLD) terminology increasingly used in UK and European clinical practice, though many NHS and NICE materials continue to use the older designation of non-alcoholic fatty liver disease (NAFLD)
The results demonstrated that semaglutide met the standard for non-inferiority to placebo for cardiovascular safety
There are multiple amylins in phase II trials, including Amycretin (another dual amylin/GLP-1 agonist, Novo Nordisk) and Eloralintide (a single-target amylin analogue, Eli Lilly)
Subsequent research expanded to dual agonists like tirzepatide (GLP-1/GIP), paving the way for Retatrutide, which uniquely integrates GLP-1, GIP, and glucagon receptor activity
A landmark, randomized, double-blind renal health study: reduces the risk of major kidney disease events by 24%, 50% greater decline in eGFR or death from renal/CV causes reduces cardiovascular (CV) events by 18%, and 20% reduction in all-cause mortality in patients with type 2 diabetes and chronic kidney disease